Current Issue

VOL 8 • NO 6 SEP/OCT 2017


Breast Implants and Lymphoma: What Is the Risk for Your Patient?

Pamela Hallquist Viale, RN, MS, CNS, ANP

Breast implants require a surgical procedure and placement of medical devices designed to give the appearance of a natural-looking female breast. This surgery may be implemented for cosmetic reasons to augment the breast or to provide breast tissue after mastectomy or damage to the breast. In can...

Original Research

Assessing the Plain Language Planner for Communication About Common Palliative Care Medications

Elaine Wittenberg,(1) PhD, Betty Ferrell,(2) RN, PhD, MA, FAAN, FPCN, CHPN, and Joy Goldsmith,(3) PhD

Clear communication about pain medication and symptoms is necessary to ensure oncology patients and family caregivers understand the purpose of the medication, can anticipate side effects, and are able to administer medication on their own. Patient-centered pain management addresses the different...

Review Article

Cancer Pain Management: Opioid Analgesics, Part 2

Rita J. Wickham, PhD, RN, AOCN®

Opioids—mu (μ) agonists and buprenorphine—are essential for managing moderate to severe cancer pain. They have no analgesic ceiling, and doses can usually be escalated to pain relief without unmanageable side effects. Key strategies are to individualize opioid doses and schedules, weigh benefits ...

Grand Rounds

Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner

Christopher J. Campen,(1) PharmD, BCOP, Wendy H. Vogel,(2) MSN, FNP, AOCNP®, and Pooja J. Shah,(3) PharmD, BCPS

Drug-interaction related risk factors include the use of drugs that are significantly impacted by inhibition or induction of drug metabolism (tyrosine kinase inhibitors [TKIs]), the use of drugs that have a significant inhibitory or inducing capacity of drug metabolism (certain antifungal medicat...

Grand Rounds

Brentuximab Vedotin Infusion Reaction Management: A Case Study

Holly Comer, MSN, APRN, and Kimbra Cardwell, MSN, APRN

Infusion reactions have been reported with brentuximab vedotin therapy in both clinical trial settings (Younes et al., 2010) and in the post clinical trial experience (Baxley, Kumm, Bishop, Medina, & Holter-Chakrabarty, 2013). Infusion reactions can range from minor grade 1 infusion reactions...

Practice Matters

Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin

Mary Alma Welch,(1) PA-C, Joanne C. Ryan,(2) PhD, RN, and Ilene Ann Galinsky,(3) BSN, MSN, ANP-C

Successfully conducting oncology clinical trials requires the involvement of various research personnel. Advanced practice providers (APPs) are integral members of the team and play a vital role in identifying and enrolling appropriate patients, educating participants, and providing supportive ca...

Practice Matters

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen

Gannel Jean-Pierre, DNP, APRN, OCN®

Prostate cancer is the second-leading cause of cancer death in male Americans, behind only lung cancer. It is estimated there will be 161,360 new cases and 26,730 deaths due to prostate cancer in 2017 (American Cancer Society [ACS], 2017). There are several treatment options for patients diagnose...

Prescriber's Corner

Venetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic Leukemia

Michelle A. Borg, PharmD, and Amber Clemmons, PharmD, BCOP

Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by abnormal numbers of mature B lymphocytes, which can accumulate in the bloodstream, as well as lymph nodes and/or bone marrow. Patients may be diagnosed incidentally upon review of routine laboratory testing and do not...

Tools and Technology

The Oncology Care Model for Advanced Practitioners

Wendy H. Vogel, MSN, FNP, AOCNP®

The Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM) is a new, multipayer model that focuses on higher quality, coordinated oncology care (CMS, 2016a). The OCM will be undertaken for a 5-year period from July 1, 2016, to June 30, 2021. Practices and payers applied for ...



Section Seperator
Section Seperator
Section Seperator
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me